These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 15067721

  • 1. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC.
    J Comp Neurol; 2004 May 17; 473(1):97-106. PubMed ID: 15067721
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The protective effect of vitamin E on locus coeruleus in early model of Parkinson's disease in rat: immunoreactivity evidence.
    Pasbakhsh P, Omidi N, Mehrannia K, Sobhani AG, Ragerdi Kashani I, Abbasi M, Kord Valeshabad A.
    Iran Biomed J; 2008 Oct 17; 12(4):217-22. PubMed ID: 19079535
    [Abstract] [Full Text] [Related]

  • 5. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine.
    Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel VM.
    J Neurosci; 1996 Jul 01; 16(13):4135-45. PubMed ID: 8753875
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Exp Neurol; 2004 Jul 01; 188(1):65-73. PubMed ID: 15191803
    [Abstract] [Full Text] [Related]

  • 10. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M, Desmond TJ, Albin RL, Frey KA.
    Synapse; 2001 Sep 15; 41(4):329-36. PubMed ID: 11494403
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability.
    Kanaan NM, Kordower JH, Collier TJ.
    J Comp Neurol; 2007 Jun 10; 502(5):683-700. PubMed ID: 17436290
    [Abstract] [Full Text] [Related]

  • 13. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration.
    Lu W, Wolf ME.
    Brain Res Mol Brain Res; 1997 Oct 03; 49(1-2):137-48. PubMed ID: 9387873
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ.
    Mov Disord; 1997 Nov 03; 12(6):885-97. PubMed ID: 9399211
    [Abstract] [Full Text] [Related]

  • 17. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y, Kordower JH.
    Neurobiol Dis; 2007 Jan 03; 25(1):134-49. PubMed ID: 17055279
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
    Staal RG, Sonsalla PK.
    J Pharmacol Exp Ther; 2000 May 03; 293(2):336-42. PubMed ID: 10773000
    [Abstract] [Full Text] [Related]

  • 19. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
    Dal Bo G, Bérubé-Carrière N, Mendez JA, Leo D, Riad M, Descarries L, Lévesque D, Trudeau LE.
    Neuroscience; 2008 Sep 22; 156(1):59-70. PubMed ID: 18706980
    [Abstract] [Full Text] [Related]

  • 20. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
    Faherty CJ, Raviie Shepherd K, Herasimtschuk A, Smeyne RJ.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):170-9. PubMed ID: 15790541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.